JP2014526450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526450A5 JP2014526450A5 JP2014528990A JP2014528990A JP2014526450A5 JP 2014526450 A5 JP2014526450 A5 JP 2014526450A5 JP 2014528990 A JP2014528990 A JP 2014528990A JP 2014528990 A JP2014528990 A JP 2014528990A JP 2014526450 A5 JP2014526450 A5 JP 2014526450A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ahr
- pharmaceutical composition
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531861P | 2011-09-07 | 2011-09-07 | |
| US61/531,861 | 2011-09-07 | ||
| PCT/EP2012/067504 WO2013034685A1 (en) | 2011-09-07 | 2012-09-07 | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526450A JP2014526450A (ja) | 2014-10-06 |
| JP2014526450A5 true JP2014526450A5 (enExample) | 2015-08-06 |
| JP6047160B2 JP6047160B2 (ja) | 2016-12-21 |
Family
ID=46832380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528990A Active JP6047160B2 (ja) | 2011-09-07 | 2012-09-07 | 天然ａｈｒリガンド依存性癌を治療および／または予防するための手段および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9593062B2 (enExample) |
| EP (1) | EP2753315B1 (enExample) |
| JP (1) | JP6047160B2 (enExample) |
| KR (1) | KR20140074330A (enExample) |
| CN (1) | CN104023713A (enExample) |
| AU (1) | AU2012306285B2 (enExample) |
| BR (1) | BR112014004937A2 (enExample) |
| CA (1) | CA2846275C (enExample) |
| ES (1) | ES2626015T3 (enExample) |
| HK (1) | HK1201471A1 (enExample) |
| IL (1) | IL231107A (enExample) |
| MX (1) | MX348941B (enExample) |
| RU (1) | RU2640913C2 (enExample) |
| WO (1) | WO2013034685A1 (enExample) |
| ZA (1) | ZA201401011B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2953065B2 (ja) | 1990-12-28 | 1999-09-27 | 石川島播磨重工業株式会社 | 宇宙飛翔体 |
| CA3173052A1 (en) | 2013-08-30 | 2015-03-05 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| IL250833B (en) | 2014-08-29 | 2022-09-01 | Univ Texas | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3274053A4 (en) | 2015-03-23 | 2018-12-05 | The Brigham and Women's Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| EP3423483B1 (en) | 2016-03-02 | 2025-09-24 | Board Of Regents Of the University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| CN107510694B (zh) * | 2016-06-16 | 2022-03-29 | 中国科学院上海巴斯德研究所 | 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用 |
| CN106214673A (zh) * | 2016-08-31 | 2016-12-14 | 深圳市第二人民医院 | 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途 |
| WO2018085775A1 (en) * | 2016-11-04 | 2018-05-11 | Ohio State Innovation Foundation | Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor |
| CN111163766A (zh) | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | Ahr抑制剂和其用途 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3096549A1 (en) | 2018-04-16 | 2019-10-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
| RU2699932C1 (ru) * | 2018-11-14 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ прогнозирования риска развития рака печени у экспериментальных животных |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| CN114828863A (zh) | 2019-10-17 | 2022-07-29 | 医肯纳肿瘤学公司 | 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途 |
| BR112022013673A2 (pt) * | 2020-01-10 | 2022-09-13 | Ikena Oncology Inc | Inibidores de ahr e seus usos |
| CN114019164B (zh) * | 2020-12-31 | 2023-11-21 | 中国科学院生态环境研究中心 | 筛选抗胶质瘤药物的方法和试剂盒 |
| CN112807305A (zh) * | 2020-12-31 | 2021-05-18 | 中国科学院生态环境研究中心 | Ch223191在抑制肿瘤细胞迁移中的应用 |
| CN114470238A (zh) * | 2022-03-25 | 2022-05-13 | 华中科技大学同济医学院附属协和医院 | AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用 |
| CN121378137A (zh) * | 2025-11-05 | 2026-01-23 | 青岛大学 | 一种芳香烃受体ahr抑制剂ch223191的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| JP4587652B2 (ja) | 2002-09-09 | 2010-11-24 | 株式会社フラバミン | 新規フラボノイド化合物及びその利用 |
| KR20050095859A (ko) * | 2003-02-04 | 2005-10-04 | 가부시키가이샤 야쿠루트 혼샤 | 유방암 내성 단백 저해제 |
| EP2023910B1 (en) * | 2006-05-03 | 2013-06-19 | Symrise AG | Ah receptor antagonists |
| WO2010008427A1 (en) | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
-
2012
- 2012-09-07 HK HK15102080.0A patent/HK1201471A1/xx unknown
- 2012-09-07 AU AU2012306285A patent/AU2012306285B2/en active Active
- 2012-09-07 BR BR112014004937A patent/BR112014004937A2/pt not_active Application Discontinuation
- 2012-09-07 EP EP12758452.2A patent/EP2753315B1/en active Active
- 2012-09-07 WO PCT/EP2012/067504 patent/WO2013034685A1/en not_active Ceased
- 2012-09-07 ES ES12758452.2T patent/ES2626015T3/es active Active
- 2012-09-07 CN CN201280043522.9A patent/CN104023713A/zh active Pending
- 2012-09-07 JP JP2014528990A patent/JP6047160B2/ja active Active
- 2012-09-07 CA CA2846275A patent/CA2846275C/en active Active
- 2012-09-07 RU RU2014104696A patent/RU2640913C2/ru active
- 2012-09-07 MX MX2014002776A patent/MX348941B/es active IP Right Grant
- 2012-09-07 KR KR1020147009041A patent/KR20140074330A/ko not_active Ceased
- 2012-09-07 US US14/343,350 patent/US9593062B2/en active Active
-
2014
- 2014-02-10 ZA ZA2014/01011A patent/ZA201401011B/en unknown
- 2014-02-24 IL IL231107A patent/IL231107A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014104696A (ru) | Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr | |
| Krantz et al. | Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression | |
| Qian et al. | Exosomes derived from hypoxic glioma deliver miR-1246 and miR-10b-5p to normoxic glioma cells to promote migration and invasion | |
| Zhou et al. | miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1 | |
| Luo et al. | The effects of aberrant expression of LncRNA DGCR5/miR‐873‐5p/TUSC3 in lung cancer cell progression | |
| Zhai et al. | Inhibition of autophagy and tumor growth in colon cancer by miR-502 | |
| Kanlikilicer et al. | Therapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models | |
| EA201391470A1 (ru) | Замещенные соли 2,3-дигидроимидазо[1,2-c]хиназолина | |
| Kopczyńska | Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel | |
| Dong et al. | MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation | |
| Xu et al. | Long noncoding RNA AC003092. 1 promotes temozolomide chemosensitivity through miR-195/TFPI-2 signaling modulation in glioblastoma | |
| JP2018513104A5 (enExample) | ||
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| Feng et al. | RBM15 silencing promotes ferroptosis by regulating the TGF‐β/Smad 2 pathway in lung cancer | |
| Sun et al. | Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| HRP20200636T1 (hr) | Indukcija male molekule trail genoma u normalnim i tumorskim stanicama kao antikancerogena terapija | |
| EA201490418A1 (ru) | Новые макроциклические соединения в качестве ингибиторов фактора xia | |
| Wang et al. | Circular RNAs: new biomarkers of chemoresistance in cancer | |
| UA107675C2 (xx) | Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом | |
| Liu et al. | [Retracted] miR‐451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor | |
| MX2021008261A (es) | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. | |
| JP2016531563A5 (enExample) | ||
| Zhan et al. | JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells | |
| Guo et al. | Long intergenic non-protein coding RNA 511 promotes the progression of osteosarcoma cells through sponging microRNA 618 to upregulate the expression of maelstrom |